New lung cancer drug shows promise in Head-to-Head trial
NCT ID NCT06280196
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called BAT3306 against the standard treatment Keytruda, both combined with chemotherapy, in 162 people with advanced non-small cell lung cancer. The goal was to see if BAT3306 works as well as Keytruda in shrinking tumors. The trial was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery
- Lung cancer study seeks to map patient journeys